200,000+ products from a single source!

sales@angenechem.com

Home > Fluorides > 101477-55-8

101477-55-8

101477-55-8 | Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-

CAS No: 101477-55-8 Catalog No: AG0004KU MDL No:MFCD00866181

Product Description

Catalog Number:
AG0004KU
Chemical Name:
Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-
CAS Number:
101477-55-8
Molecular Formula:
C27H30F2N2O3
Molecular Weight:
468.5355
MDL Number:
MFCD00866181
IUPAC Name:
1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
InChI:
InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3
InChI Key:
JQSAYKKFZOSZGJ-UHFFFAOYSA-N
SMILES:
COc1c(ccc(c1OC)OC)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F
UNII:
DEE37CY4VO

Properties

Complexity:
568  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
468.222g/mol
Formal Charge:
0
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
468.545g/mol
Monoisotopic Mass:
468.222g/mol
Rotatable Bond Count:
8  
Topological Polar Surface Area:
34.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.9  

Literature

Title Journal
Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma. Investigative ophthalmology & visual science 20120822
Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. Molecular and cellular biochemistry 20111201
Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats. Pharmacology, biochemistry, and behavior 20110201
Alleviation of brain hypoperfusion after preventative treatment with lomerizine in an elderly migraineur with aura. International journal of molecular imaging 20110101
Neuroprotective effects of flavonoids on hypoxia-, glutamate-, and oxidative stress-induced retinal ganglion cell death. Molecular vision 20110101
Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. Molecular vision 20110101
Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Die Pharmazie 20100701
Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. CNS neuroscience & therapeutics 20100401
Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. Brain research bulletin 20100316
Early events of secondary degeneration after partial optic nerve transection: an immunohistochemical study. Journal of neurotrauma 20100201
A case of ocular hypertension complicated by SUNCT syndrome. Annals of ophthalmology (Skokie, Ill.) 20100101
Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorganic & medicinal chemistry letters 20091115
Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine. Investigative ophthalmology & visual science 20091101
Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. Journal of pharmacological sciences 20091001
[Calcium antagonists in the prophylactic treatment of migraine]. Brain and nerve = Shinkei kenkyu no shinpo 20091001
[New developments in glaucoma medical treatment]. Archivos de la Sociedad Espanola de Oftalmologia 20091001
Secondary degeneration of the optic nerve following partial transection: the benefits of lomerizine. Experimental neurology 20090301
Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine. Clinical neuropharmacology 20090101
[CADASIL]. Brain and nerve = Shinkei kenkyu no shinpo 20081101
Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood. Journal of pharmacological sciences 20080901
[Migraine improved by amlodipine medication in a case with hypertension]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20080901
Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive. Psychiatry and clinical neurosciences 20080601
Plasma intact fibroblast growth factor 23 levels in women with anorexia nervosa. BioPsychoSocial medicine 20080101
Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist. Acta oto-laryngologica. Supplementum 20071201
Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorganic & medicinal chemistry letters 20070201
[Cluster like headache in a patient with the Maffucci's syndrome]. No to shinkei = Brain and nerve 20060601
CJZ3, a lomerizine derivative, modulates P-glycoprotein function in rat brain microvessel endothelial cells. Acta pharmacologica Sinica 20060401
A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. Current eye research 20060301
Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain research 20060203
[Prophylactic treatment of migraine]. Nihon rinsho. Japanese journal of clinical medicine 20051001
[Reversal of multidrug resistance by lomerizine in K562/ADM cells]. Yao xue xue bao = Acta pharmaceutica Sinica 20040501
Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovascular drug reviews 20040101
[Effects of changes in conformation and configuration of N-containing compounds on NMR spactra]. Yao xue xue bao = Acta pharmaceutica Sinica 20031201
Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Investigative ophthalmology & visual science 20031101
Validation of scanning laser Doppler flowmetry for retinal blood flow measurements in animal models. Current eye research 20020501
Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biological & pharmaceutical bulletin 20010501
Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010401

Related Products

© 2019 Angene International Limited. All rights Reserved.